Synergy Pharmaceuticals (SGYP) leaps on positive test results

Synergy Pharmaceuticals Inc

shares rose 39.4% to $6.47 following the report of positive results from Phase 3 trial of Plecanatide. Share volume was 7.4 million, better than triple its all-day average